Third- Or Later-Line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice

Clinical Colorectal Cancer - United States
doi 10.1016/j.clcc.2018.11.002
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

ARCTIC: Durvalumab With or Without Tremelimumab as Third-Line or Later Treatment for Metastatic Non-Small Cell Lung Cancer

Annals of Oncology
MedicineOncologyHematology
2020English

Therapy for Metastatic Colorectal Cancer

Oncologist
Cancer ResearchMedicineOncology
2006English

Exemestane as Third and Fourth Line Hormonal Therapy for Metastatic Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2000English

First-Line Therapy for Metastatic Colorectal Cancer: Current Perspectives and Future Directions

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2019English

Irinotecan Monotherapy as Third-Line or Later Treatment in Advanced Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2017English

Xeloda as First-Line Therapy of Metastatic Colorectal Cancer-Our Experience

Archive of Oncology
OncologyHematology
2002English

Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
2012English

No Evidence for Changes in Skeletal Muscle Mass or Weight During First-Line Chemotherapy for Metastatic Colorectal Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy